Mistletoe Preparation Iscador: Are there Methodological Concerns with Respect to Controlled Clinical Trials?

Renatus Ziegler, Renatus Ziegler

Abstract

In Europe many cancer patients use complementary therapies, particularly mistletoe. Only a few controlled clinical trials have been performed with the mistletoe preparation Iscador as a complementary treatment for cancer, many of them with medium to low quality due to methodological shortcomings. Reasons for some quality concerns, particularly discontinuation of treatment and/or participation and premature termination are analyzed. Analysis is based on controlled clinical trials dealing with Iscador. Data stem from the archive of published and ongoing research of the <<Verein für Krebsforschung>> (Society for Cancer Research) in Arlesheim, Switzerland. Controlled clinical studies with cancer patients that were started after 01.01.1990 or were not completed by then have been evaluated. Fifty-six controlled studies are documented, 24 of them randomized and 32 non-randomized. Nine of the randomized studies were done by matched-pair design, the others by conventional parallel group design; six of the last were terminated prematurely primarily for slow recruitment due to patient preferences and compliance of physicians. Patient and physician preference seem to be important factors limiting recruitment for randomized trials and hence implementation. This adds to the overall unwillingness of participation by patients with serious diseases. A well-balanced mix of designs using different research methods and outcomes is suggested combined with analyses, in countries where mistletoe therapy in general or Iscador in particular is unknown or not available.

Figures

Figure 1.
Figure 1.
Controlled clinical studies for cancer patients with the mistletoe preparation Iscador; started after or not finished by 01.01.1990.

References

    1. Cassileth BR, Deng G. Complementary and alternative therapies for cancer. Oncologist. 2004;9:80–9.
    1. Moschen R, Kemmler G, Schweigkofler H, Holzner B, Dünser M, Richter R, et al. Use of alternative/complementary therapy in breast cancer patients – a psychological perspective. Support Care Cancer. 2001;9:267–74.
    1. Kienle GS, Kiene H. Die Mistel in der Onkologie: Fakten und konzeptionelle Grundlagen. Stuttgart: Schattauer; 2004.
    1. Kienle GS, Berrino R, Büssing A, Portalupi E, Rosenzweig S, Kiene H. Mistletoe in cancer: a systematic review on controlled clinical trials. Eur J Med Res. 2003;8:109–19.
    1. Kienle GS, Kiene H. Klinische Studien zur Misteltherapie der Krebserkrankung – Eine Übersicht. Erfahrungsheilkunde. 2004;53:193–209.
    1. Kienle GS, Kiene H. Complementary cancer therapy: a systematic review of prospective clinical trials on anthroposophic mistletoe extracts. Eur J Med Res. 2007;12:1–17.
    1. Ziegler R. Klinische Versuche und Beobachtungsstudien seit 1990 mit Mistelextrakten, insbesondere Iscador. Internes Dokument. Arlesheim: Vereins für Krebsforschung; 2006.
    1. Urech K, Ziegler R. Documentation of Published Clinical Trials and Observational Studies with Iscador. Arlesheim: Verein für Krebs forschung; ( ); June 2006.
    1. USNational Institutes of Health. National Cancer Institute: Mistletoe extracts (PDQ) ( )
    1. Daems WF. Ita Wegman und das erste Mistelpräparat Iscar zur Krebsbehandlung. In: Leroi R, editor. Misteltherapie - Eine Antwort auf die Herausforderung Krebs: Die Pioniertat Rudolf Steiners und Ita Wegmans. Stuttgart: Freies Geistesleben; 1987. pp. 35–44.
    1. Büssing A. Biological and pharmacological properties of Viscum album L. In: Büssing A, editor. Mistletoe: The Genus Viscum. Amsterdam: Harwood Academic Publisher; 2000. pp. 123–82.
    1. Büssing A. Mistel (Viscum album) – anthroposophischer und phytotherapeutischer Ansatz. In: Münstedt K, editor. Ratgeber Unkonventionelle Methoden. Landsberg: Ecomed; 2003. pp. 184–99.
    1. Büssing A, Schietzel D, Schietzel M, Schink M, Stein GM. Keine Stimulation in-vitro-kultivierter Tumorzellen durch Mistellektin. Dtsch Z Onkol. 2004;36:33–70.
    1. Büssing A. Pharmakologische Wirkungen von Mistelextrakten. In: Fintelmann V, editor. Onkologie auf anthroposophischer Grundlage. Stuttgart: Mayer (1. Lieferung); 2002. Section 3.2.4.1.
    1. Flückiger H, Baumgartner S. Auswirkungen des Iscador-Maschinenprozesses auf Mistelextrakte in botanischen Untersuchungssystemen. Merkurstab. 2003;56:114–21.
    1. Matthiessen PF, Tröger W. Die Misteltherapie des Krebses. In: Wrba H, editor. Kombinierte Tumortherapie - Grundlagen, Möglichkeiten und Grenzen adjuvanter Methoden. Stuttgart: Hippokrates; 1995. pp. 271–90.
    1. Stein GM, Berg PA. Adverse effects during therapy with mistletoe extracts. In: Büssing A, editor. Mistletoe - The Genus Viscum. Amsterdam: Harwood Academic Publishers; 2000. pp. 195–208.
    1. Saller R, Kramer S, Iten F, Melzer J. Unerwünschte Wirkungen der Misteltherapie bei Tumorpatienten - Eine systematische Übersicht. In: Scheer R, Bauer R, Becker H, Fintelmann V, Kemper FH, Schilcher H, editors. Fortschritte in der Misteltherapie: Aktueller Stand der Forschung und klinische Anwendung. Essen: KVC Verlag; 2005. pp. 367–403.
    1. Saller R, Reichling J, Melzer J. Die Misteltherapie. Erwünschte und unerwünschte Wirkungen in der wissenschaftlichen Diskussion - Teil 1. PraxisMagazin. 2005;21:6–14.
    1. Saller R, Reichling J, Melzer J. Die Misteltherapie. Erwünschte und unerwünschte Wirkungen in der wissenschaftlichen Diskussion - Teil 2. PraxisMagazin. 2005;22:6–17.
    1. Bock PR, Friedel WE, Hanisch J, Karasmann M, Schneider B. Wirksamkeit und Sicherheit der komplementären Langzeitbehandlung mit einem standardisierten Extrakt aus Europäischer Mistel (Viscum album L.) zusätzlich zur konventionellen adjuvanten onkologischen Therapie bei primärem, nicht metastasiertem Mammakarzinom. Ergebnisse einer multizentrischen, komparativen, retrolektiven, epidemiologischen Kohortenstudie in Deutschland und der Schweiz. Arzneim/Drug Res. 2004;54:456–66.
    1. Augustin M, Bock PR, Hanisch J, Karasmann M, Schneider B. Safety and efficacy of the long-term adjuvant treatment of primary intermediate – to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract: results from a multicenter, comparative, epidemiological cohort study in Germany and Switzerland. Arzneim/Drug Res. 2005;55:38–49.
    1. Rostock M, Huber R. Randomized and double blind studies - demands and reality as demonstrated by two examples of mistletoe research. Forsch Komplementarmed. 2004;11(Suppl 1):18–22.
    1. Prescott RJ, Gillespie WJ, Counsell CE, Grant AM, Ross S, Russell IT, et al. Factors that limit the quality, number and progress of randomised controlled trials. In: Black N, Brazier J, Fitzpatrick R, Reeves BC, editors. Health Services Research Methods: A Guide to Best Practice. London: BMJ Books; 1998. pp. 86–97.
    1. Prescott RJ, Counsell CE, Gillespie WJ, Grant AM, Russell IT, Kiauka S, et al. Factors that limit the quality, number and progress of randomised controlled trials. Health Technol Assess. 1999;3:1–134.
    1. Ross S, Grant AM, Counsell CE, Gillespie WJ, Russell IT, Prescott RJ. Barriers to participation in randomised controlled trials: a systematic review. J Clin Epidemiol. 1999;52:1143–56.
    1. Ellis PM. Attitudes towards and participation in randomised clinical trials in oncology: a review of the literature. Ann Oncol. 2000;11:939–45.
    1. King M, Nazareth I, Lampe F, Bower P, Chandler M, Morou M, et al. Conceptual framework and systematic review of the effects of participants’ and professionals preferences in randomised controlled trials. Health Technol Assess. 2005;9:1–186.
    1. Robinson EJ, Kerr CEP, Stevens AJ, Lilford RJ, Braunholtz DA, Edwards SJL, et al. Lay public's understanding of equipoise and randomisation in randomised clinical trials. Health Technol Assess. 2005;9:1–192.
    1. Abel U. Spezielle Forschungsprobleme, Teil 1: Warum gibt es in der unkonventionellen Medizin so wenige aussagekräftige Studien? In: Bühring M, Kemper FH, editors. Naturheilverfahren und Unkonventionelle Medizinische Richungen, Sektion 01: Allgemeiner Teil. Vol. 01.08, Teil 1. Heidelberg: Springer, 1998, 1–8.
    1. Abel U. Grundlagen der Biometrie. In: Beuth J, editor. Grundlagen der Komplementäronkologie. Stuttgart: Hippokrates; 2002. pp. 45–62.
    1. Hürny C, Heusser P, Bernhard J, Castiglione M, Cerny T. Verbessern nicht-konventionelle Zusatztherapien die Lebensqualität von Krebspatienten? – Eine methodenkritische Literaturübersicht. Schweiz Med Wochenschr. 1994;124(Suppl 62):55–63.
    1. Heusser P. Probleme von Studiendesigns mit Randomisation, Verblindung und Placebogabe. Forsch Komplementarmed. 1999;6:89–102.
    1. Salzer G, Danmayr E, Wutzlhofer F, Frey S. Adjuvante Iscador-Behandlung operierter nicht kleinzelliger Bronchuskarzinome. Ergebnisse einer randomisierten Studie. Dtsch Z Onkol. 1991;23:93–98.
    1. Kleeberg U, Suciu S, Bröcker EB, Ruiter DJ, Chartier C, Liénard D, et al. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial: rIFN-a2b versus rIFN-g versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness > 3 mm) or regional lymph node metastasis. Europ J Cancer. 2004;40:390–402.
    1. Von Rohr E, Pampallona S, Van Wegberg B, Hürny C, Bernhard J, Heusser P, et al. Experiences in the realisation of a research project on anthroposophical medicine in patients with advanced cancer. Schweiz Med Wochenschr. 2000;130:1173–84.
    1. Borrelli E. Valutazione della qualità di vita in pazienti affette da adenocarcinoma mammario sottoposte a terapia con Viscum album. Med Biol. 1999,:27–30.
    1. Schink M, Tröger W, Dabidian A, Goyert A, Scheuerecker H, Meyer J, et al. Mistletoe extract reduces the surgical suppression of natural killer cell activity in cancer patients. A randomized phase III trial. Forsch Komplementarmed. 2007;17:9–17.
    1. Gerhard I, Abel U, Loewe-Mesch A, Huppmann S, Kuehn JJ. Problematik randomisierter Studien in der Komplementärmedizin dargestellt am Beispiel der Misteltherapie bei Patientinnen mit Mammakarzinom. Forsch Komplementarmed. 2004;11:150–57.
    1. Von Hagens C, Loewe-Mesch A, Kuehn JJ, Abel U, Gerhard I. Prospektive kontrollierte nicht randomisierte Machbarkeits-Studie zu einer postoperativen simultanen Mistel-/Chemotherapie bei Patientinnen mit Mammakarzinom - Ergebnisse zu Rekrutier- und Randomisierbarkeit, Immunparametern, Lebensqualität und Verträglichkeit. In: Scheer R, Bauer R, Becker H, Fintelmann V, Kemper FH, Schilcher H, editors. Fortschritte in der Misteltherapie: Aktueller Stand der Forschung und klinische Anwendung. Essen: KVC Verlag; 2005. pp. 567–78.
    1. Dold U, Edler L, Mäurer CM, Müller-Wening D, Sakellariou B, Trendelenburg F, et al. Krebszusatztherapie beim fortgeschrittenen nicht-kleinzelligen Bronchialkarzinom - Multizentrische kontrollierte Studie zur Prüfung der Wirksamkeit von Iscador und Polyerga. Stuttgart: Thieme; 1991.
    1. Eggermont AM, Kleeberg U, Ruiter DJ, Suciu S. European organization for research and treatment of cancer melanoma group trial experience with more than 2000 patients, evaluating adjuvant treatment with low or intermediate doses of interferon alpha-2b. In: Perry MC, editor. Educational Book, 37th Annual Meeting. Alexandria VA: American Society of Clinical Oncology; 2001. pp. 88–93.
    1. Grossarth-Maticek R, Ziegler R. Randomisierte Kohortenstudien im Matched-Pair-Design zur Misteltherapie (Iscador) bei gynäkologischen Karzinomen. In: Scheer R, Bauer R, Becker H, Fintelmann V, Kemper FH, Schilcher H, editors. Fortschritte in der Misteltherapie: Aktueller Stand der Forschung und klinische Anwendung. Essen: KVC Verlag; 2005. pp. 611–23.
    1. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. J Am Med Assoc. 2001;285:1987–91.
    1. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med. 2001;134:663–94.
    1. Zelen M. A new design for randomized clinical trials. N Engl J Med. 1979;300:1242–45.
    1. Zelen M. Randomized consent designs for clinical trials: an update. Stat Med. 1990;9:645–56.
    1. Altman DG, Whitehead J, Parmar MK, Stenning SP, Fayers PM, Machin DM. Randomised consent design in cancer clinical trials. Eur J Cancer. 1995;31A:1934–44.
    1. Grossarth-Maticek R, Ziegler R. Prospective controlled cohort studies on long-term therapy of breast cancer patients with a mistletoe preparation (Iscador) Forsch Komplementarmed. 2006;13:285–92.
    1. Grossarth-Maticek R, Kiene H, Baumgartner S, Ziegler R. Use of Iscador, an extract of European mistletoe (Viscum album), in cancer treatment: prospective nonrandomized and randomized matched-pairs studies nested within a cohort study. Altern Ther Health Med. 2001;7:57–78.
    1. Grossarth-Maticek R, Ziegler R. Randomised and non-randomised prospective controlled cohort studies in matched pair design for the long-term therapy of breast cancer patients with a mistletoe preparation (Iscador): a re-analysis. Europ J Med Res. 2006;11:485–95.
    1. Grossarth-Maticek R, Ziegler R. Prospective controlled cohort studies on long-term therapy of cervical cancer patients with a mistletoe preparation (Iscador) Forsch Komplementarmed. 2007;14:140–47.
    1. Montori VM, Guyatt GH. Intention-to-treat principle. Can Med Assoc J. 2001;165:1339–41.
    1. Windeler J. Das Intention-to-treat-Prinzip in klinischen Arzneimittelprüfungen. Arzneimitteltherapie. 1993;11:103–11.
    1. Sheiner LB, Rubin DB. Intention-to-treat analysis and the goals of clinical trials. Clin Pharmacol Ther. 1995;57:6–15.
    1. Sheiner LB. Is intent-to-treat analysis always (ever) enough? Br J Clin Pharmacol. 2002;54:203–11.
    1. Grossarth-Maticek R, Kiene H, Baumgartner S, Ziegler R. Addendum to Iscador article. Altern Ther Health Med. 2001;7:26.
    1. Grossarth-Maticek R, Kiene H, Baumgartner S, Ziegler R. Verlängerung der Überlebenszeit von Krebspatienten unter Misteltherapie (Iscador) - Ergebnisse einer epidemiologischen Langzeitstudie. Schweiz Z Ganzheitsmed. 2001;13:217–25.
    1. Grossarth-Maticek R, Kiene H, Baumgartner S, Ziegler R. Synergieeffekte von Selbstregulation und Misteltherapie (Iscador) auf die Überlebenszeit bei Krebspatienten - Ergebnisse einer epidemiologischen Langzeitstudie, Teil II. Schweiz Z Ganzheitsmed. 2004;16:81–9.
    1. Auerbach L, Dostal V, Václavik-Fleck I, Kubista E, Rosenberger A, Rieger S, et al. Signifikant höherer Anteil aktivierter NK-Zellen durch additive Misteltherapie bei chemotherapierten Mamma-Ca-Patientinnen in einer prospektiv-randomisierten doppelblinden Studie. In: Scheer R, Bauer R, Becker H, Fintelmann V, Kemper FH, Schilcher H, editors. Fortschritte in der Misteltherapie: Aktueller Stand der Forschung und klinische Anwendung. Essen: KVC; 2005. pp. 543–54.
    1. Nygren P, Glimelius B. The Swedish council on technology assessment in health care (SBU) report on cancer chemotherapy - project objectives, the working process, key definitions and general aspects of cancer trial methodology and interpretation. Acta Oncol. 2001;40:155–65.
    1. Deeks JJ, Dinnes J, D’Amico R, Sowden A, Sakarovitch C, Song F, et al. Evaluating non-randomised intervention studies. Health Technol Assess. 2003;7:1–173.
    1. Reeves BC. Reasons for caution when evaluating health care interventions using non-randomised study designs. Forsch Komplementarmed. 2004;11(Suppl 1):40–5.
    1. Kovacs E. Serum levels of IL-12 and the production of IFN-gamma, IL-2 and IL-4 by peripheral blood mononuclear cells (PBMC) in cancer patients treated with Viscum album extract. Biomed Pharmacother. 2000;54:305–10.
    1. Kovacs E. Viscum album und Interleukin-6 - Was ist daran? In: Scheer R, Bauer R, Becker H, Berg PA, Fintelmann V, editors. Die Mistel in der Tumortherapie Grundlagenforschung und Klinik. Essen: KVC Verlag; 2001. pp. 315–25.
    1. Kovacs E, Kuehn JJ. Measurements of IL-6, soluble IL-6 receptor and soluble gp130 in sera of B-cell lymphoma patients. Does VISCUM ALBUM treatment affect these parameters? Biomed Pharmacother. 2002;56:152–58.
    1. Kovacs E. Effects of Viscum album extract therapy in patients with cancer: relation with interleukin-6, soluble interleukin-6 receptor, and soluble gp130. J Altern Complement Med. 2004;10:241–46.
    1. Pampallona S, Von Rohr E, Van Wegberg B, Bernhard J, Helwig S, Heusser P, et al. Socio-demographic and medical characteristics of advanced cancer patients using conventional or complementary medicine. Onkologie. 2002;25:165–170.
    1. Toelg M, Reiss B, Antonu H. Chemotherapie mit begleitender Misteltherapie - Prospektive, nicht randomisierte, kontrollierte, offene Studie (AWB) zur Lebensqualität. CO’MED. 2005;11:18–22.
    1. Toelg M, Antonu H, Reiss B, Ramos MH. Lebensqualität von Tumorpatientinnen unter begleitender Misteltherapie - Ergebnisse einer prospektiven, nicht randomisierten, kontrollierten, offenen Studie (AWB) mit Iscador M. Schweiz Z Ganzheitsmed. 2005;17:294–99.
    1. Büssing A, Bischof M, Hatzmann W, Bartzsch F, Soto-Vera D, Fronk E-M, et al. Beeinflussung der Granulozytenfunktion durch einmalige perioperative Mistelextrakt-Infusion. Dtsch Z Onkol. 2004;36:148–53.
    1. Büssing A, Bischof M, Hatzmann W, Bartzsch F, Soto Vera D, Fronk E-M, et al. Beeinflussung der Granulozytenfunktion durch eine perioperative Infusion eines fermentierten Mistelextraktes. In: Scheer R, Bauer R, Becker H, Fintelmann V, Kemper FH, Schilcher H, editors. Fortschritte in der Misteltherapie: Aktueller Stand der Forschung und klinische Anwendung. Essen: KVC Verlag; 2005. pp. 555–66.
    1. Büssing A, Bischof M, Hatzmann W, Bartsch F, Soto Vera D, Fronk E-M, et al. Prevention of surgery-induced suppression of granulocyte function by intravenous application of a fermented extract from Viscum album L. in breast cancer patients. Anticancer Res. 2005;25:4753–58.
    1. Büssing A. Immune modulation using mistletoe (Viscum album L.) extracts Iscador. Arzneim/Drug Res. 2006;56:508–15.
    1. Carlsson M, Arman M, Backman M, Hamrin E. Perceived quality of life and coping for Swedish women with breast cancer who choose complementary medicine. Cancer Nurs. 2001;24:395–401.
    1. Carlsson M, Arman M, Backman M, Flatters U, Hatschek T, Hamrin E. Evaluation of quality of life/life satisfaction in women with breast cancer in complementary and conventional care. Acta Oncol. 2004;43:27–34.
    1. Carlsson M, Arman M, Backman M, Hamrin E. Coping in women with breast cancer in complementary and conventional care over 5 years measured by the mental adjustment to cancer scale. J Altern Complement Med. 2005;11:441–47.
    1. Carlsson M, Arman M, Backman M, Flatters U, Hatschek T, Hamrin E. A five-year follow-up of quality of life in women with breast cancer in anthroposophic and conventional care. Evid Based Complement Alternat Med. 2006;3:523–31.
    1. Klopp R, Schmidt W, Werner E, Werner M, Niemer W, Beuth J. Influence of complementary Viscum album (Iscador) administration on microcirculation and immune system of ear, nose and throat carcinoma patients treated with radiation and chemotherapy. Anticancer Res. 2005;25:601–10.
    1. Ziegler R. Elements of therapeutic research structure. Forsch Komplementarmed. 2004;11(Suppl 1):5–12.
    1. Ziegler R. Möglichkeiten und Grenzen klinischer Studien mit Iscador. Mistilteinn. 2004;5:44–73.
    1. Reeves BC, Gaus W. Guidelines for reporting non-randomised studies. Forsch Komplementarmed. 2004;11(Suppl 1):46–52.
    1. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon: stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med. 1985;312:1604–08.
    1. Ziegler R. Neue Studien zum Mammakarzinom und zum malignen Melanom mit dem Mistelpräparat Iscador. In: Streit E, Rist L, editors. Ethik und Wissenschaft in der anthroposophischen Medizin. Bern: Peter Lang; 2006. pp. 95–114.
    1. Bock PR, Friedel WE, Hanisch J, Karasmann M, Schneider B. Retrolective, comparative, epidemiological cohort study with parallel groups design for evaluation of efficacy and safety of drugs with “well established use” - experience with the long-term treatment using the European mistletoe extract (Viscum album L.) in addition to conventional oncologic therapy in primary, non-metastatic breast carcinoma. Forsch Komplementarmed. 2004;11(Suppl 1):23–29.
    1. Schneider B. Beobachtungsstudien zum Nachweis der Wirksamkeit von Arzneimitteln. Dtsch Z integrative Onkol. 2004;2:22–7.
    1. Hellan J, Danmayr E, Hellan M. Stellenwert der Komplementärmedizin in der Behandlung onkologischer Patienten - dargestellt anhand des kolo-rektalen Karzinoms. Dtsch Z Onkol. 1995;27:85–94.
    1. Schaefermeyer G, Schaefermeyer H. Treatment of pancreatic cancer with Viscum album (Iscador): a retrospective study of 292 patients 1986–1996. Complement Ther Med. 1998;6:172–77.
    1. Stumpf C, Rieger S, Schietzel M. Retrospektive Untersuchung zur Therapie mit Mistelextrakten bei Mammakarzinom. Dtsch Z Onkol. 2005;37:106–13.
    1. Ziegler R. Neuere klinische Studien mit Iscador zum Mammakarzinom und malignen Melanom. Mistilteinn. 2004;5:74–99.
    1. Schumacher M, Davis CE. Combining randomized and nonrandomized patients in the statistical analysis of clinical trials. Recent Results Cancer Res. 1988;111:130–37.
    1. Schmoor C, Olschewski M, Schuhmacher M. Randomized and non-randomized patients in clinical trials: experiences with comprehensive cohort studies. Stat Med. 1996;15:263–71.
    1. Olschewski M, Schumacher M, Davis K. Analysis of randomized and non-randomized patients in clinical trials using the comprehensive cohort follow-up study design. Control Clin Trials. 1992;13:226–39.
    1. Chow SC, Liu JP. Design and Analysis of Clinical Trials: Concepts and Methodologies. New York: John Wiley & Sons; 1998.
    1. Piantadosi S. Clinical Trials: A Methodologic Perspective. New York: John Wiley & Sons; 1997.
    1. Schumacher M, Schulgen G. Methodik klinischer Studien. Berlin-Heidelberg: Springer; 2002.
    1. Wahner-Roedler DL, Vincent A, Elkin PL, Loehrer LL, Cha SS, Bauer BA. Physicians’ attitudes toward complementary and alternative medicine and their knowledge of specific therapies: a survey at an academic medical center. Evid Based Complement Alternat Med. 2006;3:495–501.
    1. Von Rohr E, Pampallona S, Van Wegberg B, Cerny T, Hürny C, Bernhard J, et al. Attitudes and beliefs towards disease and treatment in patients with advanced cancer using anthroposophiscal medicine. Onkologie. 2000;23:558–63.
    1. Walach H, Falkenberg T, Fønnebø V, Lewith G, Jonas WB. Circular instead of hierarchical: methodological principles for the evaluation of complex interventions. BMC Med Res Methodol. 2006;6(Suppl 29):1–9.
    1. Heusser P. Kriterien zur Beurteilung des Nutzens von komplementärmedizinischen Methoden. Forsch Komplementarmed. 2001;8:14–23.
    1. Rosenbaum PR. Observational Studies. 2nd. New York: Springer; 2002.
    1. Hulley SB, Cummings SR, Browner WS, Grady D, Hearst N, Newman TB. Designing Clinical Research. Philadelphia: Lippincott Williams & Wilkins; 2001.
    1. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med. 2000;342:1878–86.
    1. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342:1887–92.
    1. MacLehose RR, Reeves BC, Harvey IM, Sheldon TA, Russell IT, Black AM. A systematic review of comparisons of effect sizes derived from randomised and non-randomised studies. Health Technol Assess. 2000;4:1–145.
    1. Reeves BC, MacLehose RR, Harvey IM, Sheldon TA, Russell IT, Black AM. Comparison of effect sizes derived from randomised and non-randomised studies. In: Black N, Brazier J, Fitzpatrick R, Reeves BC, editors. Health Services Research Methods: A Guide to Best Practice. London: BMJ Books; 1998. pp. 73–85.
    1. Shadish WR, Cook TD, Campbell DT. Experimental and Quasi-Experimental Designs for Generalized Causal Inference. Boston: Houghton Mifflin; 2002.
    1. Heusser P, Berger Braun S, Ziegler R, Bertschy M, Helwig S, Van Wegberg B, Cerny T. Palliative in-patient cancer treatment in an anthroposophic hospital: I. Treatment patterns and compliance with anthroposophic medicine. Forsch Komplementarmed. 2006;13:94–100.
    1. Heusser P, Berger Braun S, Bertschy M, Burkhard R, Ziegler R, Helwig S, et al. Palliative in-patient cancer treatment in an anthroposophic hospital: II. Quality of life during and after stationary treatment, and subjective treatment benefits. Forsch Komplementarmed. 2006;13:156–66.
    1. Hajto T, Hostanska K, Berki T, Palinkas L, Boldizsar F, Nemeth P. Oncopharmacological perspectives of a plant lectin (Viscum album Agglutinin-I): overview of recent results from in vitro experiments and in vivo animal models, and their possible relevance for clinical applications. Evid Based Complement Alternat Med. 2005;2:59–67.
    1. Klopp R. Immunmodulation mit Iscador. Schweiz Z GanzheitsMed. 2001;13:290–91.
    1. Wispler MJ, Kappler M, Soto Vera D, Reif M, Schnelle M, Zänker KS. Prospektive, randomisierte, kontrollierte Studie zur Aktivierung des Homings und des allgemeinen Aktivitätsniveaus von T-Lymphozyten durch subkutane Mistelextrakt-Injektionen bei gesunden männlichen Probanden. In: Scheer R, Bauer R, Becker H, Fintelmann V, Kemper FH, Schilcher H, editors. Fortschritte in der Misteltherapie: Aktueller Stand der Forschung und klinische Anwendung. Essen: KVC Verlag; 2005. pp. 513–25.
    1. Huber R, Klein R, Berg PA, Lüdtke R, Werner M. Effects of a lectin and viscotoxin rich mistletoe preparation on clinical and hematological parameters: a placebo controlled evaluation in healthy subjects. J Altern Complement Med. 2002;8:857–66.
    1. Klein R, Classen K, Berg PA, Lüdtke R, Werner M, Huber R. In vivo- induction of antibodies to mistletoe lectin-1 and viscotoxin by exposure to aqueous mistletoe extracts: a randomised double- blinded placebo controlled phase I study in healthy individuals. Eur J Med Res. 2002;7:1–9.
    1. Huber R, Classen K, Werner M, Klein R. In-vitro-Immunreaktion gegen Lektin-reiche und Viscotoxin-reiche Mistel (Viscum album L.)-Extrakte Iscador nach Verabreichung an gesunde Probanden - Eine randomisierte doppelblinde Plazebo-kontrollierte Studie. Arzneim/Drug Res. 2006;56:447–56.
    1. Huber R, Rostock M, Goedl R, Lüdtke R, Urech K, Buck S, et al. Mistletoe treatment induces GM-CSF- and IL-5 production by PBMC and increases blood granulocyte- and eosinophil counts: a placebo-controlled randomized study in healthy subjects. Eur J Med Res. 2005;10:411–18.
    1. Huber R, Rostock M, Goedl R, Lüdtke R, Urech K, Klein R. Immunologic effects of mistletoe lectins: a placebo-controlled study in healthy subjects. J Soc Integr Oncol. 2006;4:3–7.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner